AOL Money & Finance

Feed

Cramer on BloggingStocks: Sanofi has lots of upside catalysts

TheStreet.com's Jim Cramer says it looks like the patent worries aren't so dire after all.

Now that we see that health care reform is not going to bring price caps or socialization of medicine, we are beginning to see some real expansion in the drug stocks, including Merck (MRK) (Cramer's Take), Bristol-Myers (BMY) (Cramer's Take) and Lilly (LLY) (Cramer's Take). But there is one drug stock that is continually met with skepticism -- Sanofi Aventis (SNY) (Cramer's Take), the French vaccine and pharmaceutical maker run by Christian Viehbacher. The resistance is obvious, as his biggest two drugs are coming off patent very soon, and his hope is that by 2013 the company might again reach 2008 levels.

Sounds like there's no reason to buy this one. Sounds like its 4% dividend isn't safe.

Continue reading Cramer on BloggingStocks: Sanofi has lots of upside catalysts

Lilly's stock meanders, but remains a Buy

Eli Lilly & Co. (NYSE: LLY) stock has unexpectedly meandered since the June 8, 2009 Buy recommendation at a price of $34.10, but the aforementioned probably represents selected investor jitters about the likely, federal health care reform legislation.

Ignore those jitters. The major components of health care reform have not been determined as of September 30, 2009, but the pharma calculation remains the same as it was in June. The legislation will be net-positive for major pharmaceutical companies, under the thesis that there will be 30-45 million more U.S. residents regularly - as opposed to sporadically - accessing health care services over the next decade, not including population growth.

Continue reading Lilly's stock meanders, but remains a Buy

Seven dividend elites: 100 years of dividends

"While companies have been cutting dividends at an historic pace over the last 24 months, the fact is that there are still quality companies with long histories of paying dividends that represent good long-term investments," says Chuck Carlson, a specialist in companies offering dividend reinvestment plans.

In his top-notch The DRIP Investor he says, "The seven stocks featured here have each been paying a dividend for over 100 years, have raised their dividend annually for at least the last quarter century and offer direct-purchase plans.

Continue reading Seven dividend elites: 100 years of dividends

Options Update: DuPont and Eli Lilly calls active on dividend play

DuPont (NYSE: DD) closed at $32.57. August 11 DD options were active on volume of 349,770 contracts into today's ex-dividend. DD August option implied volatility of 33; September is at 35; below its 26-week average 43 according to Track Data, suggesting decreasing price movement.

Eli Lilly (NYSE: LLY) closed at $33.18. LLY goes ex dividend today with a 49 cents dividend. On August 11 LLY options were active on volume of 28,953 contracts. LLY August option implied volatility is at 28, September is at 27; below its 26-week average of 31, suggesting decreasing price movement.

Options Update: Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Analyst calls: MCO, VALE, GS, CSCO, PALM, LLY, JBHT, PTR

Analyst upgrades:
  • Deutsche Bank upgraded HealthSouth (NYSE: HLS) and Rehabcare (NYSE: RHB) to Buy from Hold after raising its Post Acute Care sector view to Positive from Neutral. The firm believes volumes and margin leverage can drive better than expected Q2 results and 2009 guidance. The firm raised its target on HealthSouth shares to $16 from $12 and on Rehabcare to $28 from $19.
  • Jefferies upgraded Moody's (NYSE: MCO) to Hold from Underperform to reflect stabilizing credit markets and its belief regulatory concerns are overstated. The firm raised its target on shares to $30 from $19.
  • Keefe Bruyette upgraded Goldman Sachs (NYSE: GS) to Outperform from Market Perform as it finds the stock inexpensive following the better than expected results. The firm has a $195 target on shares.
  • Vale (NASDAQ: VALE) was upgraded to Buy from Neutral at BofA/Merrill.
  • CNOOC (NYSE: CEO) was upgraded to Overweight from Equal Weight at Morgan Stanley.
  • International Game Tech (NYSE: IGT) was upgraded to Buy from Neutral at Janney Montgomery.

Continue reading Analyst calls: MCO, VALE, GS, CSCO, PALM, LLY, JBHT, PTR

Five stocks for Father's Day from Kiplinger's ... and five more

Every year I find myself asking the same question: What to get dad for Father's Day. Well, Kiplinger's offers not to get our dads the same old presents -- another tie, another power tool -- but stocks in companies he probably likes or uses their products. That's a great idea, I thought, and decided to counter with five of my own.
  • Kiplinger's suggests: Diageo (NYSE: DEO), the seller of such brands as Johnnie Walker, Smirnoff, Guinness and José Cuervo. Diageo has held up better than most during the recession -- thanks to a balanced portfolio of products, with higher exposure to mid-price, mainstream brands and less exposure to ultra-premium brands. The shares look reasonably priced. At $56.01, Diageo trades at 15 times estimated June 2009 earnings of $3.82 a share. The stock yields 2.8%.
  • Another to consider: Molson Coors (NYSE: TAP), the seller of such brands as Coors, Blue Moon, Pilsner and Rickard's. Beer, probably even more so than hard liquor is supposed to hold better during a recession given the cheaper price point. The company's recent quarterly profits more than doubled. The shares trade at 13 times forward earnings of $3.33 and yield 2.2%.

Continue reading Five stocks for Father's Day from Kiplinger's ... and five more

Cramer on BloggingStocks: Don't fight the Obama phalanx

TheStreet.com's Jim Cramer says there'll be a time to buy health care. But wait until the smoke clears.

Please don't tell me we are back in the world of no institutional memory again. That all that happened is we dropped enough points to freak everyone out, get the bears out of hibernation and then it is onward and upward. Nothing would shock me, especially the vehemence with which everyone hated the market again Monday.

If you replay what happened, most of the issues stemmed from statements made by the same Europeans that have said no more stimulus is needed, the same Europeans who have been in denial the whole way publicly, but believe me they have been stimulating like mad because their banks are a much larger size relative to their gross domestic product than ours and are in many ways worse off.

Continue reading Cramer on BloggingStocks: Don't fight the Obama phalanx

Time to scoop up some shares of Lilly

Readers of this space know that the investment bias is toward large-cap companies with demonstrated business models and who have a competitive advantage in established markets, preferably with a favorable, global trend as a support. And with the aforementioned in mind, Eli Lilly & Co. (NYSE: LLY) is worth a review.

In general, analysts see a 5-7% revenue gain in FY2009 for Lilly, led by growth in sales of branded drugs Cymbalta, Humalog, Cialis, and Alimta. Meanwhile, sales of Zyprexa and Gemzar are likely to decline this year.

Continue reading Time to scoop up some shares of Lilly

Cramer on BloggingStocks: 'Tells' of the beta trade

TheStreet.com's Jim Cramer suggests watching certain staples for hints that the flight to riskier plays is losing steam.

Will the endless "beta" trade out of slow-moving, "safe" drugs and foods and into companies like Freeport-McMoRan (NYSE: FCX) (Cramer's Take) and Caterpillar (NYSE: CAT) (Cramer's Take) ever end?

I think it won't end here, that's for certain, unless your staples stock goes to a 5% yield and the economy's macro data show a further breakdown. If we get some retail sales that are awful and some employment numbers that show a further trashing, then we are going to see a momentary blip up in stocks like Pepsi (NYSE: PEP) (Cramer's Take) and Clorox (NYSE: CLX) (Cramer's Take), but perhaps no more than that.

Continue reading Cramer on BloggingStocks: 'Tells' of the beta trade

Eli Lilly posts quarterly earnings

Earlier today, pharmaceutical firm Eli Lilly (NYSE: LLY) announced that it suffered a fourth-quarter loss thanks to charges suffered when purchasing ImClone Systems. Excluding these charges, LLY tallied $1.07 per share in the quarter -- topping analysts' estimates for $1.05 per share. Taking the ImClone acquisition (which cost LLY $4.73 billion in charges) into account, LLY lost $3.31 per share during the quarter. Quarterly revenue checked in at $5.42 billion.

Continue reading Eli Lilly posts quarterly earnings

Stocks in the news: SBUX, F, LLY, MMM, LLY, MO, QCOM, ALL, WFC ...

Ford Motor Co. (NYSE: F) posted a loss of $5.9 billion, or $2.46 per share, in the fourth quarter, but it said that it still has no plans to seek federal aid unless economic conditions worsen. Ford burned through $5.5 billion in cash during the quarter. Excluding one-time items, Ford lost $1.37 per share, below estimates of a loss of $1.30 per share. Revenue fell to $29.2 billion, down from $45.5 billion for the fourth quarter of 2007. Ford's shares are gaining nearly 2.5% in premarket trading. Fifteen minutes after the open, Ford shares were 2.2% lower.

Starbucks (NASDAQ: SBUX) reported worse-than-expected quarterly results late Wednesday after the close, as its quarterly profit dropped 69%. It also also announced 6,700 more job cuts and plans to close 300 stores. As the company has been hurt by tighter consumer spending, it said it will not provide any sales or earnings guidance. SBUX shares are defclining over 4% in premarket trading. Fifteen minutes after the open, SBUX shares were flattish.

Continue reading Stocks in the news: SBUX, F, LLY, MMM, LLY, MO, QCOM, ALL, WFC ...

Old fashioned businesses that still make money, 5 easy ways to beat money stress & fame in family - Today in Money 1/15

cIn the News:
The Biggest Insurance Scheme of All Time?
UnitedHealth Group, one of the country's largest insurers, settled what may be one of the largest health insurance schemes of all time on Tuesday after allegedly cheating sick patients out of hundreds of millions of dollars. And it probably would not have happened without Mary Jerome, an advanced-stage ovarian cancer patient who finally just said "enough" after getting hit with $46,000 in medical bills – even though she had top-notch insurance coverage.
http://www.cnbc.com/id/28643259

Continue reading Old fashioned businesses that still make money, 5 easy ways to beat money stress & fame in family - Today in Money 1/15

Stocks in the news: AAPL, JPM, BAC, GOOG, MOT, LLY, INTC, STX ...

JPMoragn Chase (NYSE: JPM) has amazingly managed to surprise Wall Street when it reported its quarterly results this morning. Maybe that's why it decided to report six days early. JPMorgan even managed to avoid a loss in the fourth quarter, perhaps a sign it is managing much better than others during this crisis than other banks. Of course, it wasn't that rosy as its reported profit of $702 million, or 7 cents per share, was down sharply -- 76% -- from $2.97 billion, or 86 cents per share, a year ago. Analysts expected break-even results. Shares were 3% higher in premarket trading.

Apple Inc. (NASDAQ: AAPL)
CEO Steve Jobs announced Wednesday after the close he is taking a medical leave of absence until the end of June. COO Tim Cook will be taking over Jobs' day-to-day operations, but Jobs said he'll still be involved in strategic decisions. When shares resumed trading in after-hours, they were down some 8%. Only last week Jobs said he suffers from a hormone imbalance that caused him to lose weight, but that he will remain CEO during his recovery. This has been quite the reversal that he says is due to his problems being "more complex" than originally thought.
This morning, also, Bloomberg reports that Jobs "could be facing surgery to remove his pancreas," according to doctors.
Apart from Jobs illness, though, Gartner has released a preliminary report on U.S. and worldwide PC shipment, which places Apple in fourth place in U.S market share at 8.0% in the fourth quarter, down from 9.5% in the third quarter of 2008.
RBC Capital Mkts downgraded AAPL from Sector Perfrom to Underperform. Oppenheimer lowered its target price from $135 to $120.
AAPL shares were down 7% in premarket trading.

Continue reading Stocks in the news: AAPL, JPM, BAC, GOOG, MOT, LLY, INTC, STX ...

Cramer on BloggingStocks: Cramer bullish on the Dow for '09 -- Part IV

TheStreet.com's Jim Cramer looks at the next six components of the Dow, including a lousy drug company and a winning financial.

This is the fourth part of Jim Cramer's series of predictions for the Dow components in 2009. Be sure to read the first, second and third parts.

JPMorgan Chase
(NYSE: JPM) (Cramer's Take): Jamie Dimon is revered, but we are in a tough market for the consumer in 2009, which truly worries me. That said, the stock has been killed by Dimon's own pessimistic projections, and I don't believe they will pan out as badly as he does.

The dividend appears safe, and I believe that the second half of the year will see some lending improvement and merger activity. I see it going back to where it did a huge equity offering at $39 a share, a nice appreciation from this beaten-down level. It's good, but I believe that Wells Fargo's (NYSE: WFC) (Cramer's Take) performance will give it a run for the money.

My one worry here is the purchase of Washington Mutual. This was another deal that looked great when the Resolution Mortgage Trust part of TARP was still alive -- I don't believe that it would have been worth buying Washington Mutual without it. But that's all too late, and now JPMorgan has to rationalize the two entities and cut costs as aggressively as possible, something Jamie Dimon knows to do better than anyone in the banking world ... with the exception of Wells Fargo.

Continue reading Cramer on BloggingStocks: Cramer bullish on the Dow for '09 -- Part IV

Next Page »

Symbol Lookup
IndexesChangePrice
DJIA+30.6910,464.40
NASDAQ+6.872,176.05
S&P 500+4.981,110.63

Last updated: November 26, 2009: 01:23 PM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance